Patent application number | Description | Published |
20080249095 | 1-Acyldihydropyrazole Derivatives - Compounds of the formula (I), in which R | 10-09-2008 |
20080293719 | Pyridiazinone Derivatives for the Treatment of Tumours - Compounds of the formula (I), in which R | 11-27-2008 |
20080306052 | 3, 6-Dihydro-2-Oxo-6H-1,3,4,-Thiadiazine Derivatives - Compounds of the formula I, in which R1, R2, Q and B have the meanings indicated in claim | 12-11-2008 |
20080312278 | Hydroxyquinoline Derivatives - Compounds of the formula I in which X, Y, R | 12-18-2008 |
20080318936 | Substituted 5-Phenyl-3,6-Dihydro-2-Oxo-6H-1,3,4-Thiadiazines -
Compounds of the formula (I), in which R | 12-25-2008 |
20090054459 | Substituted indoles - Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R | 02-26-2009 |
20090163556 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS - The present invention relates to glycinamide derivatives of formula I, | 06-25-2009 |
20090291963 | SUBSTITUTED INDOLES - Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R | 11-26-2009 |
20090298885 | METHYLENE UREA DERIVATIVES - The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. | 12-03-2009 |
20100179148 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 07-15-2010 |
20100179149 | ARYL ETHER PYRIDAZINONE DERIVATIVES - Compounds of the formula I, in which R | 07-15-2010 |
20100197690 | Pyrimidinyl Pyridazinone Derivatives - Compounds selected from the group according to Claim | 08-05-2010 |
20100234354 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 09-16-2010 |
20100261697 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES - Compounds of the formula (I) in which R | 10-14-2010 |
20100273796 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS - Compounds of the formula I | 10-28-2010 |
20100280030 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS - Compounds of the formula (I), in which R | 11-04-2010 |
20100311733 | THIADIAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 12-09-2010 |
20110034474 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 02-10-2011 |
20110071153 | DIHYDROPYRAZOLE DERIVATIVES AS TYROSINE KINASE MODULATORS FOR THE TREATMENT OF TUMORS - Compounds of the formula I, in which R | 03-24-2011 |
20110092498 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS - Compounds of the formula (I), in which R | 04-21-2011 |
20110135600 | BICYCLIC TRAIZOLE DERIVATIVES FOR TREATING OF TUMORS - Compounds of the formula (I), in which X | 06-09-2011 |
20110136819 | 6-THIOXOPYRIDAZINE DERIVATIVES - Compounds of the formula I, in which R | 06-09-2011 |
20110257172 | 3-(3-Pyrimidine-2-yl-benzyl)-[1,2,4] triazolo[4,3-b]pyrimidine derivatives - Compounds of the formula I, in which R | 10-20-2011 |
20110257173 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives - Compounds of the formula (I), in which R | 10-20-2011 |
20110257180 | Novel Polymorphic Forms of 6-(1-methyl-1H-pyrazol-4-yl)-2--2H-pyridazin-3-one Dihydrogenphosphate and Processes of Manufacturing thereof - The present invention relates to 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate, its solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer. | 10-20-2011 |
20110257181 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which Y, R | 10-20-2011 |
20110263596 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS - Described are compounds which inhibit, regulate and/or modulate kinase signal transduction, for example of Met kinase. The compounds are of the formulae A1 to A148 and B1 described herein, including 2-oxobenzoxazol-3-ylmethyl]phenyl}carbamate and 2-oxooxazolo[4,5-b]pyridin-3-ylmethyl)phenyl]carbamate compounds, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. Also described are compositions containing these compounds. Also described are methods for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role by administering these compounds. | 10-27-2011 |
20110269756 | BENZOTHIAZOLONE DERIVATIVES - Compounds of the formula I, in which R | 11-03-2011 |
20110269765 | Pyridazinone derivatives - Compounds of the formula (I) in which D, R | 11-03-2011 |
20110269767 | Novel Polymorphic Forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile Hydrochloride Salt and Processes of Manufacturing Thereof - The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer. | 11-03-2011 |
20110269771 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which D, R | 11-03-2011 |
20120295908 | PYRIMIDINYL PYRIDAZINONE DERIVATIVES - Compounds selected from the group according to claim | 11-22-2012 |
20130131037 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 05-23-2013 |
20130158076 | Methylene Urea Derivatives - The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. | 06-20-2013 |
20130184260 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 07-18-2013 |
20130184261 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 07-18-2013 |
20130190311 | Pyridazinone derivatives - Compounds of the formula I | 07-25-2013 |
20140128396 | PYRIMIDINYL PYRIDAZINONE DERIVATIVES - Compounds selected from the group according to Claim | 05-08-2014 |
20140148463 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I) in which D, R | 05-29-2014 |
20140200221 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF - The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer. | 07-17-2014 |